1. Taiwan, Province of China Stocks

  2. •

    Healthcare

  3. •

    Medical - Diagnostics & Research
Welgene Biotech Co.,Ltd.

Welgene Biotech Co.,Ltd.

6661.TWO
Welgene Biotech Co.,Ltd.TW flagTaipei Exchange
18.25
TWD
+0.45
- -
425.30MMarket Cap

Total Valuation

Welgene Biotech Co.,Ltd. carries a market capitalization of 425.30M, placing it among publicly traded companies globally. Its enterprise value stands at 392.30M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap425.30M
Enterprise Value392.30M

Share Statistics

Welgene Biotech Co.,Ltd. currently has 23.30M shares outstanding.

Shares Outstanding23.30M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

Welgene Biotech Co.,Ltd. trades at a trailing price-to-earnings ratio of 323.71. The price-to-sales ratio is 1.15, and the price-to-book ratio stands at 1.86.

PE Ratio323.71
PS Ratio1.15
PB Ratio1.86
P/TBV Ratio1.51
P/FCF Ratio5.62
P/OCF Ratio12.21

Enterprise Valuation

On an enterprise value basis, Welgene Biotech Co.,Ltd. trades at an EV/EBITDA multiple of 6,882.51 and an EV/FCF ratio of 4.91. The EV/Sales ratio of 1.04 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 6,882.51 provides insight into valuation relative to core operating earnings.

EV / Sales1.04
EV / EBITDA6,882.51
EV / EBIT6,882.51
EV / FCF4.91

Financial Position

Welgene Biotech Co.,Ltd. maintains a current ratio of 2.21, meaning it holds 2.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 79.01, indicating elevated leverage, while an interest coverage ratio of 0.02 demonstrates limited ability to service its debt obligations.

Current Ratio2.21
Quick Ratio1.64
Debt / Equity79.01
Debt / EBITDA3,965.39
Interest Coverage0.02

Financial Efficiency

Welgene Biotech Co.,Ltd. posts a return on equity of 0.58 and a return on invested capital of 0.01.

Return on Equity (ROE)0.58
Return on Assets (ROA)0.23
Return on Invested Capital (ROIC)0.01
Return on Capital Employed (ROCE)1.12
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover5.79

Taxes

Over the trailing twelve months, Welgene Biotech Co.,Ltd. has paid 42,000.00 in income taxes, reflecting an effective tax rate of 3.14.

Income Tax42,000.00
Effective Tax Rate3.14

Stock Price Statistics

Welgene Biotech Co.,Ltd.'s stock has declined approximately -6.88776% over the past 52 weeks. The 50-day moving average sits at 17.32, while the 200-day moving average is 18.73.

Beta (5Y)N/A
52-Week Price Change-6.88776%
50-Day Moving Average17.32
200-Day Moving Average18.73
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, Welgene Biotech Co.,Ltd. generated 375.94M in revenue and converted that into 1.33M in net income, yielding earnings per share of 0.06. EBITDA reached 57,000.00, while operating income came in at 57,000.00.

Revenue375.94M
Gross Profit156.18M
Operating Income57,000.00
Pretax Income1.34M
Net Income1.33M
EBITDA57,000.00
EBIT57,000.00
Earnings Per Share (EPS)0.06

Balance Sheet

Welgene Biotech Co.,Ltd. holds 269.03M in cash and equivalents against 226.03M in total debt, resulting in a net debt position of -43.10M. Total book value stands at 231.39M, with working capital of 199.43M providing operational flexibility.

Cash & Cash Equivalents269.03M
Total Debt226.03M
Net Debt-43.10M
Equity (Book Value)231.39M
Book Value Per Share10.00
Working Capital199.43M

Cash Flow

Welgene Biotech Co.,Ltd. produced 35.27M in operating cash flow over the past twelve months. After subtracting -41.34M in capital expenditures, free cash flow totaled -6.07M - equivalent to -0.26 per share.

Operating Cash Flow35.27M
Capital Expenditures-41.34M
Free Cash Flow-6.07M
FCF Per Share-0.26

Margins

Welgene Biotech Co.,Ltd. operates with a gross margin of 41.54, reflecting its pricing power and cost economics. The operating margin of 0.02 and net profit margin of 0.35 provide insight into operational efficiency.

Gross Margin41.54
Operating Margin0.02
Pretax Margin0.36
Profit Margin0.35
EBITDA Margin0.02

Dividends & Yields

Dividend Per ShareN/A
Dividend YieldN/A
Payout RatioN/A
Shareholder Yield-11.23
FCF Yield17.79

Stock Splits

Welgene Biotech Co.,Ltd.'s most recent stock split took place on August 17, 2018 with a 25:27 split ratio.

Last Split Date8/17/2018
Split Ratio25:27

Scores

Welgene Biotech Co.,Ltd. posts an Altman Z-Score of 1.75, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score1.75